The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 969-975

  Harris, S L ^a   Jones, D W ^a,b   Gallimore, M J ^a   Nicholls, P J ^b   Winter, M ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Antibodies to factor XII; Antiphospholipid antibodies; Antiphospholipid syndrome; Factor XII; MultipinTM peptide synthesis

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KALLIKREIN; STREPTAVIDIN; UNCLASSIFIED DRUG; ANTIGEN; MULTIPROTEIN COMPLEX; PEPTIDE; PREKALLIKREIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY COMBINING SITE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN SYNTHESIS; AMINO ACID SEQUENCE; BINDING SITE; BIOTINYLATION; CHEMISTRY; ENZYME ACTIVE SITE; IMMUNOLOGY; MACROMOLECULE; METABOLISM; MOLECULAR GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONFORMATION; REPRODUCIBILITY; SILVER STAINING;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIGENS; ANTIPHOSPHOLIPID SYNDROME; BINDING SITES; BIOTINYLATION; CATALYTIC DOMAIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XII; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROMOLECULAR SUBSTANCES; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; PEPTIDES; PREKALLIKREIN; PROTEIN CONFORMATION; REPRODUCIBILITY OF RESULTS; SILVER STAINING;

EID: 23844522946     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01334.x     Document Type: Article

References (20)

1. Ratnoff OD. Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
2. Colman RW. Biologic activities of the contact factors in vivo. Potentiation of hypotension, inflammation, and fibrinolysis and inhibition of cell adhesion and thrombosis. Thromb Haemost 1999; 82: 1568-77.
3. Schmaier AH. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr Opin Hematol 2000; 7: 261-5.
4. Griffin JH, Cochrane CG. Human factor XII (Hageman factor). In: Lorand L. cd. Methods in Enzymology XLV: Proteolytic Enzymes B. New York: Academic Press, 1976: 56-65.
5. Saito H, Ralnoff OD. Pensky J. Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 1976; 88: 506-14.
6. Hauert J. Nicoloso G, Schleuning WD, Bachmann F. Schapira M Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 1989; 73: 994-9.
7. Smith O. Gilbert M. Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
8. Ichinose A. Fujikawa K. Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
9. Jones DW. Gallimore MJ. Harris SL, Winter M. Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost 1999; 81: 387-390.
10. Jones DW. Nicholls P. Donohue S, Gallimore MJ. Winter M. Antibodies to factor XII arc distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost 2002; 87: 426-430.
11. Jones DW. Gallimore MJ. Mackie IJ. Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000; 110: 721-6.
12. Jones DW, Gallimore MJ, Winter M. Antibodies to factor XII: A possible predictive marker for recurrent foetal loss. Immunobiology 2003; 207: 43-46.
13. Gallimore MJ, Fareid E. Stormorken H. The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res 1978; 12: 409-420.
14. Wilson WA, Gharavi AE, Koike T, Lockshin MD. Branch DW. Piette JC. Brey R. Derksen R. Harris EN. Hughes GRV. Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite anliphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
15. Mcintyre JA, Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: a survey. J Autoimmun 2000; 15: 185-93.
16. Geysen HM. Rodda SJ. Mason TJ, Tribbick G, Schoofs PG. Strategies for epitope analysis using peptide synthesis. J Immunol Methods 1987; 102: 259-74.
17. McMullen BA. Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor).J Biol Chem 1985; 260: 5328-41.
18. Cool DE. Edgell C-JS. Louie GV, Zoller MJ. Brayer GD. McGillivray RTA. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. J Biol Chem 1985; 260: 13666-76.
19. Schmeidler-Sapiro KT. Ratnoff OD. Gordon EM. Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. Proc Natl Acad Sci USA 1991; 15: 4382-5.
20. Gordon EM, Venkatsen N, Salazar R, Tang H, Schmeidler-Sapiro K, Buckley S, Warburton D, Hall FL. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci USA 1996; 93: 2174-9.